Pacylex Pharmaceuticals
4000, 10230 Jasper Avenue, T5J 4P6 Edmonton, AB, Canada

Excited to see today's research published in Nature Communications picked up in a story by Fierce Biotech! https://www.fiercebiotech.com//how-a-drug-derived-from-ant #cancer, #lymphoma, #leukemia, #albertacancer, #Pacylex, #PCLX001, #UAlberta; #UAlberta_FoMD; #Worldslongestgame; #CRINA

Pacylex founder, Luc Berthiaume, featured today describing the work published today in Nature Communications. https://www.folio.ca/new-treatment-for-blood-cancer-works-/

Big news today - Pacylex research published in the journal, Nature Communications, establishes proof-of-concept for NMT inhibitors as potential cancer therapeutics and supports the continued preparation for the first human clinical trial set to begin in early 2021. https://www.nature.com/articles/s41467-020-18998-1

Pacylex founder Dr. Luc Berthiaume profiled as a Research Rockstar for his work leading to PCLX-001 as a drug candidate headed for clinical trials late this year. 8/17/20https://myleapmagazine.ca/2020/08/17/research-rockstar-dr-luc-berthiaume/

Really appreciate Pacylex being recognized in The Silicon Review's "10 Best Healthcare Companies to Watch 2020" https://thesiliconreview.com//pioneering-a-new-approach-f/

Pacylex will have our science and business spotlighted in several important meetings: The American Society of Clinical Oncology (ASCO) Annual Meeting 2020, American Association for Cancer Research (AACR) Annual Meeting 2020, and BIO Digital Meeting are great opportunities to share our research results and clinical plans for 2020. https://pacylex.reportablenews.com//pacylex-presents-as-me #oncology #medicine #cancer #pacylex #ASCO20, #AACR20, #BIODigital